Auxilius Pharma develops Value-Added Medications focused on addressing unmet medical needs in cardiovascular health. The company enhances existing pharmaceuticals to deliver improved patient outcomes through convenient dosage forms. Their lead product, AUX-001, is positioned as a first-line treatment for chronic stable angina, offering proven hospitalization reduction effects.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic stable angina patients often have limited access to effective treatments in convenient dosage forms. Existing medications may not adequately address their clinical needs or provide optimal ease of use.
Solution
Auxilius Pharma is developing reformulated medications for chronic stable angina, leveraging the 505(b)(2) regulatory pathway to expedite approval by using existing safety and efficacy data. Their lead asset, AUX-001, is an extended-release formulation of Nicorandil, an EU-approved product, intended for the US market. This new formulation aims to improve patient access to effective treatments by offering a more convenient dosage form. The company's approach focuses on value-added reformulated product candidates, utilizing expertise and technological advancements in drug formulation and manufacturing to address unmet clinical needs in cardiovascular care.
Target Audience
The primary target audience includes patients suffering from chronic stable angina and healthcare providers seeking improved treatment options.
Features
- Extended-release formulation of Nicorandil (AUX-001)
- Utilizes the 505(b)(2) regulatory pathway for accelerated approval in the US
- Reformulated medication designed for convenient dosage